Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

gp100 inhibitor

DRUG CLASS:

gp100 inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

tebentafusp-tebn (7)

tebentafusp-tebn (7)

›

HLA-A*02:01	Uveal Melanoma	HLA-A*02:01	Uveal Melanoma	tebentafusp-tebn Sensitive: A1 - Approval tebentafusp-tebn Sensitive : A1	tebentafusp-tebn Sensitive: A1 - Approval tebentafusp-tebn Sensitive : A1
HLA-A*02:01	Uveal Melanoma	HLA-A*02:01	Uveal Melanoma	ipilimumab + tebentafusp-tebn Sensitive: A2 - Guideline ipilimumab + tebentafusp-tebn Sensitive : A2	ipilimumab + tebentafusp-tebn Sensitive: A2 - Guideline ipilimumab + tebentafusp-tebn Sensitive : A2
CXCL10 elevation	Uveal Melanoma	CXCL10 elevation	Uveal Melanoma	tebentafusp-tebn Sensitive: C3 – Early Trials tebentafusp-tebn Sensitive : C3	tebentafusp-tebn Sensitive: C3 – Early Trials tebentafusp-tebn Sensitive : C3
CXCL10 elevation	Cutaneous Melanoma	CXCL10 elevation	Cutaneous Melanoma	tebentafusp-tebn Sensitive: C3 – Early Trials tebentafusp-tebn Sensitive : C3	tebentafusp-tebn Sensitive: C3 – Early Trials tebentafusp-tebn Sensitive : C3
IL6 elevation	Uveal Melanoma	IL6 elevation	Uveal Melanoma	tebentafusp-tebn Sensitive: C3 – Early Trials tebentafusp-tebn Sensitive : C3	tebentafusp-tebn Sensitive: C3 – Early Trials tebentafusp-tebn Sensitive : C3
HLA-A2 positive + PMEL overexpression	Melanoma	HLA-A2 positive + PMEL overexpression	Melanoma	durvalumab + tremelimumab + tebentafusp-tebn Sensitive: C3 – Early Trials durvalumab + tremelimumab + tebentafusp-tebn Sensitive : C3	durvalumab + tremelimumab + tebentafusp-tebn Sensitive: C3 – Early Trials durvalumab + tremelimumab + tebentafusp-tebn Sensitive : C3
HLA-A*02:01	Cutaneous Melanoma	HLA-A*02:01	Cutaneous Melanoma	durvalumab + tebentafusp-tebn Sensitive: C3 – Early Trials durvalumab + tebentafusp-tebn Sensitive : C3	durvalumab + tebentafusp-tebn Sensitive: C3 – Early Trials durvalumab + tebentafusp-tebn Sensitive : C3